Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2023-07-17 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Beyfortus approved in US for infant RSV prevention
Regulatory Filings Classification · 100% confidence The document is a formal announcement released via RNS (RNS Number : 2865G) on July 17, 2023, detailing the US FDA approval of the drug Beyfortus (nirsevimab) for preventing RSV in infants. It contains key highlights, quotes from management, and references to clinical trial data, but it is not the full Annual Report (10-K), a comprehensive Interim Report (IR), or a transcript (CT). It is a press release announcing a significant corporate/product development. Since it is a formal regulatory announcement disseminated through the RNS system, and it is not a specific financial report type like 10-K, AR, or ER (which usually focus purely on financial results), the most appropriate classification is the general regulatory announcement category, RNS, as it serves as a broad regulatory disclosure.
2023-07-17 English
TOTAL VOTING RIGHTS
Major Shareholding Notification Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. The content focuses on the total voting rights as of June 30, 2023, including share capital and voting rights information. It references the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. The document is short (3154 characters) and primarily provides an update on voting rights, which aligns with notifications about major shareholding or voting rights changes. There is no detailed financial data, management discussion, or audit information. The document is not an announcement of a report but a direct regulatory filing about voting rights. Therefore, the most appropriate classification is Major Shareholding Notification (MRQ).
2023-07-03 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a notification released via RNS (London Stock Exchange news service) dated July 3, 2023. The content explicitly states it is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1 and provides the total number of voting rights (1,549,878,574) as of June 30, 2023. This type of notification, detailing the total number of shares with voting rights, is a standard regulatory disclosure concerning capital structure and shareholder rights, but it does not fit perfectly into the specific categories like DIV, SHA, or DVA (which is for voting *results*). Since it is a formal regulatory announcement disseminated via RNS that deals with capital/voting rights information but isn't a primary financial report or a specific transaction report, it falls best under the general 'Regulatory Filings' (RNS) category, as it is a mandatory disclosure under transparency rules.
2023-07-03 English
DATO-DXD SIGNIFICANTLY IMPROVED PFS IN LUNG CANCER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by AstraZeneca PLC, which is a report of a foreign issuer pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934. It contains an announcement about clinical trial results for a drug (datopotamab deruxtecan) in lung cancer, including detailed trial data and company statements. The document is not a full annual or quarterly report, nor is it an earnings release or management discussion. It is a regulatory filing used by foreign companies to report material information to the SEC between annual reports. The document is over 13,000 characters and contains substantive information but is primarily an announcement of clinical trial results rather than a financial report or other specific filing type. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other categories.
2023-07-03 English
Dato-DXd significantly improved PFS in lung cancer
Legal Proceedings Report Classification · 99% confidence The document is identified by the 'RNS Number' header and the date stamp '03 July 2023', indicating it is a regulatory announcement disseminated via the Regulatory News Service (RNS). The content details the positive top-line results from a Phase III clinical trial (TROPION-Lung01) for a drug candidate (datopotamab deruxtecan), which is a significant corporate and scientific update. Since it is a formal announcement of clinical trial results, it fits best under the general 'Regulatory Filings' category (RNS) as it is not a full Annual Report (10-K), a specific Earnings Release (ER) focusing only on financial metrics, or a dedicated Investor Presentation (IP). It is a broad regulatory disclosure.
2023-07-03 English
ANNUAL REPORT
Annual Report Classification · 95% confidence The document is titled 'FORM 11-K' and is an annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2022. It contains detailed financial statements, including statements of net assets available for plan benefits, statements of changes in net assets, notes to financial statements, and an independent auditor's report. The 11-K form is a specific annual report filed by employee benefit plans, which is distinct from the company's 10-K annual report but still an official annual report covering financial performance. The document is substantive, over 15,000 characters, and includes full financial data and analysis, not just an announcement or certification. Therefore, it fits the category of an Annual Report (10-K) type filing, specifically the 11-K annual report for employee benefit plans.
2023-06-28 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.